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BH3 mimetics such as ABT-263 induce apoptosis in a subset of
cancer models. However, these drugs have shown limited clinical
efficacy as single agents in small-cell lung cancer (SCLC) and other
solid tumor malignancies, and rational combination strategies re-
main underexplored. To develop a novel therapeutic approach, we
examined the efficacy of ABT-263 across >500 cancer cell lines,
including 311 for which we had matched expression data for select
genes. We found that high expression of the proapoptotic gene
Bcl2-interacting mediator of cell death (BIM) predicts sensitivity to
ABT-263. In particular, SCLC cell lines possessed greater BIM tran-
script levels than most other solid tumors and are among the most
sensitive to ABT-263. However, a subset of relatively resistant
SCLC cell lines has concomitant high expression of the antiapop-
totic myeloid cell leukemia 1 (MCL-1). Whereas ABT-263 released
BIM from complexes with BCL-2 and BCL-XL, high expression of
MCL-1 sequestered BIM released from BCL-2 and BCL-XL, thereby
abrogating apoptosis. We found that SCLCs were sensitized to
ABT-263 via TORC1/2 inhibition, which led to reduced MCL-1 pro-
tein levels, thereby facilitating BIM-mediated apoptosis. AZD8055
and ABT-263 together induced marked apoptosis in vitro, as well
as tumor regressions in multiple SCLC xenograft models. In a Tp53;
Rb1 deletion genetically engineered mouse model of SCLC, the com-
bination of ABT-263 and AZD8055 significantly repressed tumor
growth and induced tumor regressions compared with either drug
alone. Furthermore, in a SCLC patient-derived xenograft model that
was resistant to ABT-263 alone, the addition of AZD8055 induced
potent tumor regression. Therefore, addition of a TORC1/2 inhibitor
offers a therapeutic strategy to markedly improve ABT-263 activity
in SCLC.
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Effective cancer-targeted therapies often trigger cell death,commonly via apoptosis, to induce remissions (1–3). For ex-
ample, we and others previously observed that, among lung can-
cers with activating EGFR mutations, those with higher expression
levels of Bcl2-interacting mediator of cell death (BIM), a key
regulator of apoptosis, have a higher response rate and longer
progression-free survivals upon treatment with EGFR inhibitors
(2, 4). BH3 mimetics are a class of drugs designed to promote
apoptosis. These compounds bind to and inhibit antiapoptotic
BCL-2 family members, the molecular sentinels of apoptosis. ABT-
263 (5) is a BH3 mimetic that directly binds BCL-2 and BCL-XL,
which blocks their binding to BIM and thereby enables BIM-
mediated induction of apoptosis (6–8). However, ABT-263 does not
bind the prosurvival BCL-2 family member myeloid cell leukemia 1
(MCL-1), and high levels of MCL-1 are associated with resistance
to BH3 mimetics such as ABT-263 in both the laboratory and the
clinic (9–17).
Small-cell lung cancer (SCLC) is a high-grade neuroendocrine
carcinoma that accounts for 10–15% of all lung cancers and is
commonly associated with a significant tobacco history. Patient
outcomes have not improved substantially over the past 30 y,
underscoring the need for more effective treatment strategies
(18). Recent studies have demonstrated the antitumor activity of
BH3 mimetics in laboratory models of SCLC (5, 19–21). These
findings spurred clinical trials of the BH3 mimetic ABT-263
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(Navitoclax) in SCLC (22). ABT-263 was well tolerated in the clinic
with a dose-limiting toxicity of thrombocytopenia (22), an on-target
toxicity of BCL-XL inhibition (23). Unfortunately, phase II trials of
ABT-263 monotherapy revealed unimpressive activity. Sixteen of 26
evaluable patients had progression of disease, 9 had stable disease,
and one had a partial response (24). Consequentially, there has
been no further clinical development of ABT-263 as a monotherapy
in SCLC.
Despite these findings, several questions remain: which solid tumor
malignancies are most sensitive to single-agent ABT-263, and why is
SCLC among the most sensitive? In addition, why does SCLC fail to
respond to single-agent ABT-263 in the clinic, and how could efficacy
be enhanced? Here, we assess the sensitivity of a large panel of cell
lines spanning multiple cancer types to ABT-263. We observe that
cell lines with high expression of BIM are highly sensitive to ABT-263
and that SCLC expresses higher levels of BIM than other solid tumor
malignancies. Although SCLC is among the most sensitive to single-
agent ABT-263, efficacy is substantially limited by MCL-1, which
also is elevated in SCLC. We find that SCLC can be sensitized to
ABT-263 via TORC1/2 inhibition, which leads to reduction of
MCL-1 protein levels, thereby permitting BIM-mediated apoptosis.
In two SCLC mouse xenograft models, either drug alone has little
activity. However, the combination ABT-263 and AZD8055 induces
tumor stabilization or regression. Furthermore, we examined the
efficacy of this combination in autochthonous lung tumors arising in
a genetically engineered mouse model (GEMM) of SCLC, where
the combination of ABT-263 and AZD8055 also induces tumor
stabilization or regression. By contrast, most tumors progress when
treated with either drug alone. Finally, in a patient-derived xeno-
graft model of SCLC in which ABT-263 alone is ineffective, the
combination of ABT-263 and AZD8055 causes tumor regression.
These studies demonstrate that the combination of ABT-263 and
AZD8055 potently suppresses tumor progression across a variety of
preclinical SCLC experimental models.
Results
BIM/MCL-1 Ratio Predicts Sensitivity to ABT-263. Our initial studies
stemmed from the observation that 5 of 11 SCLC human xenografts
tested by Shoemaker and colleagues (19) did not respond to ABT-
263 and that the majority of patients treated in a phase II study had
progression of disease (24). To more broadly identify mediators of
response to ABT-263, we examined data collected from a high-
throughput drug screen (13) assessing over 500 human cancer cell
lines for sensitivity to ABT-263. Because the mechanism underlying
ABT-263 activity putatively relies on releasing BIM to promote ap-
optosis (6), we hypothesized that BIM levels may predict re-
sponsiveness to ABT-263. By matching cell line sensitivity to two
independent gene expression data sets, we found a modest, but sig-
nificant, correlation between BIM expression and sensitivity to ABT-
263 (Fig. 1A and SI Appendix, Fig. S1A). As we and others have
reported (10, 13–17), high MCL-1 expression correlated with re-
sistance to ABT-263 and the related ABT-737, and we also observed
MCL-1–based resistance to ABT-263 across both data sets (SI Ap-
pendix, Fig. S1 B and C). However, the ratio of BIM to MCL-1
predicted sensitivity to ABT-263 more effectively than the expression
of either biomarker alone (Fig. 1B and SI Appendix, Fig. S1D).
Moreover, among cell lines, those with the highest BIM levels that
also expressed high levels ofMCL-1 were not sensitive to ABT-263
nor were those cancers with low expression of both BIM and
MCL-1, underscoring the added value of measuring the ratio of
BIM toMCL-1 in predicting sensitivity (Fig. 1C and SI Appendix, Fig.
S1E). It is notable that the ratio of either BCL-2 or BCL-XL to
MCL-1 was inferior to the ratio of BIM to MCL-1 at predicting re-
sponse to ABT-263 across solid tumor cancers (SI Appendix, Fig. S2).
These findings underlie the potential capacity for MCL-1 to mitigate
the therapeutic benefit of ABT-263 in cancers with high BIM levels.
We found that SCLC lines have increased BIM expression com-
pared with other solid tumor types (Fig. 1D and SI Appendix, Fig. S3)
along with enhanced sensitivity to ABT-263 compared with other
solid tumor types across a large panel of cancer cell lines (Fig. 1E and
SI Appendix, Fig. S4). To determine whether ABT-263 sensitivity in
SCLC was mediated by high BIM expression, we knocked down
BIM using siRNA. Knockdown with two different siRNAs
designed against BIM in SCLC cell lines consistently suppressed
ABT-263–induced apoptosis by >50% (Fig. 2 A and B and
Fig. 1. BIM/MCL-1 expression ratios predict response to ABT-263. (A) Scatter plot
of ABT-263 IC50 (μM) values on natural log scale versus relative BIM RNA ex-
pression levels measured from the Cancer Cell Line Encyclopedia (CCLE) (45) (n =
331). A linear regression analysis was used to assign a coefficient of determination
(R2) of 0.039 and a P value of 0.00043. (B) Scatter plot of ABT-263 IC50 (μM) values
on the natural log scale versus the ratio of BIM/MCL-1 expression levels. A linear
regression analysis was used to assign a coefficient of determination (R2) of 0.146
and a P value of 2.83e-12. Expression values were taken from the CCLE (45).
(C) Scatter plots comparing ABT-263 IC50 (μM) values on the natural log scale
between cell lines with high BIM expression (top 10%) and lowMCL-1 expression
(bottom 75%), cell lines with high BIM expression (top 10%) and high MCL-1
expression (top 25%), and cell lines with low BIM expression and low MCL-1 ex-
pression. Expression values were taken from the CCLE (45). An unpaired t test with
Welch’s correction was used to assign a P value for differential IC50’s between the
BIM high/MCL-1 low group and the two other groups; P = 0.0027 and P = 0.0014,
respectively. Red bars are the geometric means of the IC50’s for the groups of cell
lines. (D) Box plot showing increased expression of BIM in SCLC cell lines compared
with other solid tumors. AWilcoxon rank-sum test was used to assign a P value for
differential expression between the two groups; P value of 7.94e-06. Expression
values were taken from the CCLE (45). (E) Cancer cell lines were grouped by
cancer type, represented by a numeric value, and correlated to ABT-263 IC50 (μM)
values on natural log scale. The key for the different cancer types is in SI Ap-
pendix, Fig. S4. A box is drawn around SCLC (#21) for emphasis. Sensitive cell lines
were set at IC50’s <1 μM and insensitive cell lines >1 μM. Based on these criteria,
a P value of 0.0000033 was assigned from a two-tailed Fisher’s exact test com-
paring SCLC to other solid tumor types. Of note, there were 10 sensitive SCLC cell
lines and 11 insensitive SCLC cell lines (48% sensitive). In contrast, among all other
solid tumor types, there were 37 sensitive and 443 resistant cancers (8% sensitive).
Note that representative cancer types are shown and not every cancer type an-
alyzed is included.
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SI Appendix, Fig. S5 A and B). Next, we engineered H1048 SCLC
cells to have either modest (“low”) or marked (“high”) over-
expression of MCL-1 (Fig. 2C and SI Appendix, Fig. S5C). In-
creasing expression of MCL-1 protected cells from ABT-263–
induced apoptosis (Fig. 2D). These results support the model that
high BIM and low MCL-1 promote sensitivity to ABT-263,
whereas high MCL-1 mediates ABT-263 resistance.
To further assess the mechanism of ABT-263 response, we
performed immunoprecipitation of BIM complexes from whole-
cell lysates. Please note that the BIM immunoprecipitations
successfully depleted >90% of the cellular BIM (SI Appendix, Fig.
S5D). In control cells, ABT-263 treatment led to loss of BIM
binding to BCL-XL and BCL-2, whereas it induced BIM binding to
MCL-1 (Fig. 2E). This indicates that MCL-1 binds the BIM that is
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Fig. 2. BIM and MCL-1 mediate ABT-263–induced apoptosis in SCLC, and the ratio of BIM to MCL-1 expression predicts the magnitude of apoptosis in
SCLC cell lines. (A) SCLC SW1271 and H1048 cells were treated with either 10 nM scrambled (sc) or BIM siRNA (2), and, the next day, cells were treated with
or without ABT-263. Then, cells were (A) prepared and stained with propidium iodide and Annexin-V. Apoptosis was measured by FACS analysis of the
percentage of cells positive for Annexin-V 72 h after treatment (the amount of apoptotic cells caused by ABT-263 treatment minus no drug treatment) or
(B) lysed and separated by SDS/PAGE, subjected to Western blot, and probed with the indicated antibodies. In A, error bars are SD (n = 3); in B, the asterisk
indicates a nonspecific band. (C ) H1048 cells transduced with lentiviral particles containing plasmids that express GFP alone (control) or GFP-IRES-MCL-1.
MCL-1–overexpressing cells were sorted to isolate cells expressing low and high amounts of MCL-1 based on GFP fluorescence intensity. Protein lysates
were prepared and probed with the indicated antibodies. (D) The cells were treated with either no drug (control) or ABT-263 for 48 h. Cells were prepared
and stained with propidium iodide and Annexin-V. Apoptosis was measured by FACS analysis of the percentage of cells with Annexin-V positivity. Bars
represent mean percentage of apoptotic cells, ABT-263 treatment minus control. Error bars are SD (n = 3). (E ) BIM antibody (or IgG control) was added to
lysates following treatment with or without ABT-263 for 6 h derived from H1048 cells expressing GFP, low MCL-1, or high MCL-1 (as in C ), and BIM-
containing complexes were immunoprecipitated and separated by SDS/PAGE, subjected to Western blot, and probed with the indicated antibodies.
(F ) BIM RNA levels or (G) MCL-1 RNA levels in a panel of 10 human SCLC cell lines were determined by quantitative PCR, and the average of three
replicates was plotted versus the amount of apoptosis (n = 3) induced by 1 μM of ABT-263 over 72 h. Each dot represents a unique human SCLC line
labeled in red font, with RNA levels relative to GAPDH abundance. A linear regression analysis was used to assign, for F, a coefficient of determination (R2)
of 0.142 and a P value of 0.284 (P = not significant), and for G, a coefficient of determination (R2) of 0.135 and a P value of 0.296 (P = not significant).
(H) BIM/MCL-1 RNA levels were plotted versus apoptosis in the same lines. A linear regression analysis was used to assign a coefficient of determination
(R2) of 0.456 and a P value of 0.032. (I) SCLC H1048 cells were treated with either 50 nM scrambled (sc) or MCL-1 siRNA for 24 h. Cells were reseeded and
treated the following day with no drug (control) or ABT-263 and then prepared for FACS analysis of percentage of cells with Annexin-V positivity 24 h
after treatment. Error bars are SD (n = 3). (Right) Cell lysates were prepared from the transfected cells and separated by SDS/PAGE, subjected to Western
blot, and probed with the indicated antibodies.
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released from complexes with BCL-2 and BCL-XL upon treatment
with ABT-263. This likely contributes to the mechanism whereby
MCL-1 expression mitigates the apoptotic response induced by
ABT-263. Incremental overexpression of MCL-1 resulted in more
BIM/MCL-1 complexes (Fig. 2E) and fewer BIM/BCL-2 complexes,
consistent with the abrogation of apoptosis induced by MCL-1
overexpression. Consistent with these results and similar to the
analyses of the large cell line panel described above, BIM or MCL-1
expression alone was not significantly predictive of apoptosis fol-
lowing ABT-263 therapy in a subset of SCLC cell lines (Fig. 2 F and
G). However, the ratio of BIM/MCL-1 correlated significantly with
apoptotic response in SCLC cell lines (Fig. 2H). Thus, BIM and
MCL-1 levels substantially impact sensitivity to ABT-263–mediated
apoptosis in SCLC cell lines, with high BIM and low MCL-1 ex-
pression associated with enhanced sensitivity to ABT-263.
TORC1/2 Inhibition Suppresses MCL-1 and Sensitizes SCLC Cells to
ABT-263. Despite some of the preclinical promise of ABT-263
against SCLC (Fig. 1E) (5, 19), ABT-263 has demonstrated minimal
clinical activity in SCLC as monotherapy (22, 24). BIM levels are
higher in SCLC relative to other solid tumor cell lines (Fig. 1D and
SI Appendix, Fig. S3), but MCL-1 levels are also relatively high in
SCLC (SI Appendix, Fig. S5E), suggesting that high MCL-1 levels
may be mitigating the efficacy of ABT-263 in SCLC. Consistent
with this notion, knockdown of MCL-1 using two different siR-
NAs sensitized the H1048 SCLC cell line to ABT-263 (Fig. 2I
and SI Appendix, Fig. S6A). We therefore sought to identify
pharmacological strategies that could suppress MCL-1 levels and
increase sensitivity to ABT-263. We did not pursue obatoclax,
which does target MCL-1 in addition to other BCL-2 family
members, because early clinical trials suggest that obatoclax
causes toxicity independent of its effects on BCL-2 family pro-
teins, potentially limiting its clinical utility (25–27). Rather, we
considered TORC1/2 inhibitors because they suppress MCL-1
protein levels in some cancers (7, 28–31). We observed that the
TORC1/2 catalytic inhibitor AZD8055 (32) potently suppressed
protein levels of MCL-1 in SCLC cells (Fig. 3A) and markedly
enhanced ABT-263–induced apoptosis in four different SCLC
cell lines examined (Fig. 3B). BIM immunoprecipitations con-
firmed that AZD8055 abrogated the formation of MCL-1/BIM
complexes normally induced by ABT-263 treatment (Fig. 3C and
SI Appendix, Fig. S6B; compare the combination to ABT-263).
Consistent with the proposed mechanism of apoptosis induced
by this combination, overexpression of MCL-1 blocked apoptosis
induced by the combination (Fig. 3D and SI Appendix, Fig. S6 C
and D). Importantly, AZD8055 and ABT-263 interfered with cell
cycle progression in all SCLC cell lines (SI Appendix, Fig. S7).
Thus, the combination of ABT-263 and AZD8055 both in-
creased apoptosis and induced growth arrest of SCLCs, sug-
gesting that this combination could be of superior efficacy
compared with treatment uniquely targeting BCL-2 family
members. Interestingly, we found that treatment of SCLC cells
with rapamycin, an allosteric mTOR inhibitor, diminished ex-
pression of pS6, a downstream target of TORC1, but, unlike
AZD8055 therapy, failed to suppress p4E-BP1 signaling, lower
MCL-1 levels, or sensitize to ABT-263 as well as AZD8055 (SI
Appendix, Fig. S8 A and B). These data are consistent with other
studies demonstrating that TORC1/2 catalytic inhibitors more ef-
fectively suppress 4E-BP1 phosphorylation and cap-dependent
translation than rapamycin or rapalogs (31, 33). In fact, resistance
to single-agent AZD8055 has been reported to emerge through re-
activation of cap-dependent translation, including that of MCL-1,
in the presence of the drug (34). Of note, although others found
that BCL2-associated X protein (BAX) plays a role in rapamycin
sensitization of ABT-737 (35), we did not observe an increase in
BAX expression in the ABT-263/AZD8055 combination treatment
compared with ABT-263 treatment (SI Appendix, Fig. S8C) despite
the induction of substantial apoptosis (∼20%) at the same time
point (SI Appendix, Fig. S8D).
Previous studies have suggested that mTOR is necessary for effi-
cient cap-dependent translation of MCL-1, and thus mTOR inhib-
itors may decrease MCL-1 expression by decreasing translation. To
determine if AZD8055 affected the half-life of MCL-1 protein, we
treated H1048 cells with the cytoplasmic protein synthesis in-
hibitor, cycloheximide (CHX), alone or in combination with
AZD8055. We found the rate of MCL-1 protein degradation was
comparable over time in the CHX-treated cells versus the CHX+
AZD8055 combination-treated cells, suggesting a similar mode
of MCL-1 inhibition between CHX and AZD8055 (SI Appen-
dix, Fig. S9A). Treatment at 6 h with AZD8055 alone left
a nearly equivalent amount of cellular MCL-1 as CHX alone or
the combination of CHX and AZD8055 (SI Appendix, Fig. S9
A and B). These data are consistent with translational inhibition
being the major mechanism underlying suppression of MCL-1
protein levels following mTORC inhibition.
Combination of ABT-263 and AZD8055 Causes Tumor Regression in
Xenograft Models. We next assessed the efficacy of AZD8055 and
ABT-263 in vivo using H1048 and H82 SCLC cell line xenograft
tumor models. ABT-263 has been shown to be only modestly ef-
fective in the H1048 model and minimally effective in the H82 model
(19) and therefore may be more representative of SCLC clinical
outcomes with single-agent BH3 mimetics such as ABT-263 (22, 24).
Consistent with previous data (19), ABT-263 (80 mg/kg/qd) was
partially effective in established H1048 xenografts, whereas single-
agent AZD8055 (16 mg/kg/qd) modestly slowed tumor growth (Fig.
3E). However, the combination induced marked tumor regressions
to nearly undetectable sizes (Fig. 3E). In the faster-growing H82
xenografts, ABT-263 was ineffective as previously reported (19).
Single-agent AZD8055 had a modest effect on tumor growth (Fig.
3E). However, the combination almost completely blocked growth
of these tumors (Fig. 3E). Pharmacodynamic studies confirmed
that AZD8055 suppressed phosphorylation of TORC1 targets S6
and 4E-BP1 and decreased MCL-1 protein levels in vivo (Fig.
3F). Moreover, cleaved caspase 3, a marker of apoptosis, was
significantly increased following combination treatment (Fig. 3G
and SI Appendix, Fig. S10A), consistent with the in vitro studies.
No overt toxicities were observed in the tumor bearing mice
treated with the combination (SI Appendix, Fig. S10B).
Combination of ABT-263 and AZD8055 Is Superior to Either Drug
Alone in a SCLC Genetically Engineered Mouse Model. Although cell
line xenograft models of SCLC are valuable tools for assessing drug
activity in vivo, they may not fully model the tissue environment and
heterogeneity of autochthonous tumors (those growing in their native
tissue context). To rigorously assess the activity of the combination of
ABT-263 and AZD8055 in vivo, we used a GEMM of SCLC (36).
Tumors are initiated in this model via conditional inactivation
of both alleles of Tp53 and Rb1 in pulmonary neuroendocrine
cells, resulting in the development of tumors that model the
histology, metastatic spread, and acquired genetic alterations
observed in human SCLC (37–39). Tumor-bearing SCLC GEMMs
were randomized to receive no treatment, AZD8055 alone (16mg/
kg/qd), ABT-263 alone (80 mg/kg/qd), or both ABT-263 and
AZD8055 and were treated for 21 d (Fig. 4A). Magnetic resonance
imaging (MRI) of the thorax was performed 1 day before starting
treatment and on day 21 of treatment, and lung tumor volumes
pre- and posttreatment were quantified. Most animals had exactly
one measurable lung tumor. If more than one tumor was observed
in separate lobes of the lungs, the larger tumor was measured.
Only tumors that were histologically confirmed to be high-grade
neuroendocrine tumors or had clear evidence of distant metastatic
spread on MRI were included in the analysis. Tumors progressed
in all untreated animals (n = 7), although we observed significant
variability in the rate of progression over the 21-d period (Fig. 4B–D
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and SI Appendix, Table S1). All tumors treated with AZD8055 alone
progressed (n= 5) (Fig. 4 B,E, and F and SI Appendix, Table S1). Of
six tumors treated with ABT-263, five progressed and one regressed
(Fig. 4 B, G, and H and SI Appendix, Table S1). By contrast, in six
animals treated with the combination of ABT-263 and AZD8055,
three tumors regressed and three others showed relatively limited
tumor progression (Fig. 4B, I, and J and SI Appendix, Table S1). The
responses of tumors to the combination of ABT-263 and AZD8055
were significantly superior to responses either to the drug alone or to
no treatment. Consistent with these findings and those in the human
xenograft models (Fig. 3 E–G), CC3 staining in allografted SCLC
GEMM tumors was markedly apparent in the combination treat-
ment at the 3-d time point (Fig. 4 K–N), again indicating a strong
apoptotic response following administration of this regimen.
Ex vivo cell lines derived from SCLC GEMMs treated with
AZD8055 had reduction ofMCL-1 protein levels and were sensitized
Fig. 3. Combination treatment with ABT-263 and the TORC1/2 inhibitor AZD8055 leads to robust apoptosis and antitumor activity in vivo. (A and B) The indicated SCLC
cell lines were treated with no drug (–), 500 nM AZD8055, 1 μM ABT-263, or a combination of 500 nM AZD8055 and 1 μM ABT-263. (A) After 16 h of treatment, lysates
were probed with the indicated antibodies. (B) After 72 h of treatment, cells were prepared and stained with propidium iodide and Annexin-V, and apoptosis was
measured by FACS analysis of the percentage of cells with Annexin-V positivity. Bars represent mean the amount of apoptosis induced by each treatment minus control.
Error bars are SD (n= 3). **P< 0.05 by Student’s t test, ABT-263 versus combination treatment group and AZD8055 versus combination group. (C) H1048 cells were treated
with no drug (−), 1 μM ABT-263, 500 nM AZD8055, or 500 nM AZD8055/1 μMABT-263 for 2 h, and lysates were immunoprecipitated with BIM antibody or IgG negative
control. Precipitates were analyzed byWestern blot analyses with the indicated antibodies. (D) H1048 cells transducedwith lentiviral particles expressing GFP alone (GFP) or
GFP-IRES-MCL-1 (the “high”-expressingMCL-1 cells from Fig. 2C) were treatedwith either no drug (–) or 500 nMAZD8055/1 μMABT-263. Following 72 h of treatment, cells
were prepared and stained with propidium iodide and Annexin-V, and apoptosis was measured by FACS analysis of the percentage of cells with Annexin-V positivity. Bars
represent mean percentage of apoptotic cells following combination treatment over control. Error bars are SD (n = 3). (E) Human SCLC H1048 and H82 cells were grown
as xenograft tumors in Nu/Nu mice, and, when tumors were ∼100–200 mm3, mice were randomized into treatment cohorts: control (no drug), 16 mg/kg/qd AZD8055,
80 mg/kg/qd ABT-263, or the combination of AZD8055 and ABT-263. AZD8055 was given ∼1.5 h before ABT-263 for combination treatments. Tumor measurements were
performed approximately three times per week by calipers, and the average tumor volume + SEM for each cohort is displayed. (F) Tumors were harvested from H1048
tumor-bearingmice approximately 3 h after drug administration at the end of treatment and tumor lysates were subjected toWestern blot analyses and probed with the
indicated antibodies. (G) Slides were prepared from formalin-fixed tissue of H1048-tumor bearing mice approximately 3 h after drug administration and stained with CC3
to quantify apoptosis. Quantification of CC3 is shown in SI Appendix, Fig. S10A.
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to ABT-263 (SI Appendix, Fig. S11 A and B), consistent with the
mechanism delineated in human cell lines and the activity observed
in vivo.
SCLC tumors often respond to first-line chemotherapy in
patients, although these responses are almost invariably transient. To
provide context for the responsiveness to the AZD8055/ABT-263
combination in the SCLC GEMM model, we treated mice with
a combination of cisplatin (7 mg/kg IP on days 1 and 8) and eto-
poside (10 mg/kg on days 2 and 9), the standard chemotherapies
used to treat SCLC in patients. When we compared responses to
the combination chemotherapy at day 28 to responses to the tar-
geted therapy combination at day 21, the regimen of ABT-263 and
AZD8055 improved responses, although the differences did not
reach statistical significance (Fig. 4B). These data show an en-
couraging efficacy of the ABT-263/AZD8055 combination therapy
in reference to standard of care chemotherapy in this model.
AZD8055 Sensitizes a SCLC Patient-Derived Xenograft Model to ABT-263.
To further gain insight into the translational potential of our find-
ings, we next determined the efficacy of the combination in a third
type of in vivo model, a patient-derived xenograft (PDX). This type
of in vivo model may more faithfully recapitulate the high de-
gree of genomic complexity of the human disease. Patient-derived
xenografts derived from a histologically confirmed SCLC case were
implanted into NOD scid gamma (NSG) mice, and mice were
monitored for tumor growth (Fig. 5A and SI Appendix, Fig. S12).
Growing tumors were subsequently treated with either single-
agent ABT-263 (80 mg/kg/qd) (n = 4) or the combination of ABT-
263 (80 mg/kg/qd) and AZD8055 (16 mg/kg/qd) (n = 4) (there
were not enough tumor-bearing mice to treat with single-agent
AZD8055). Consistent with a recent report highlighting overall
modest activity of ABT-737 against PDXs of SCLC (35), the tumors
in all mice treated with single-agent ABT-263 grew fairly rapidly
despite drug treatment (Fig. 5A). In contrast, the addition of
AZD8055 to ABT-263 led to consistent tumor regressions and
showed no sign of regrowth when the experiment was ended
∼50 d after drug treatments began (Fig. 5A). Additionally, phar-
macodynamic analyses of the tumors demonstrated marked de-
crease in MCL-1 expression in the combination cohort (Fig. 5B).
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Fig. 4. Combination ABT-263 and AZD8055 induce tumor regressions in a GEMM of SCLC. (A) Schematic of GEMM experiment. Gray space in mouse drawing
indicates lung; red circle indicates lung tumor. (B) SCLC GEMMs harboring radiographically measurable lung tumors were randomized to receive treatment for 21 d
with 80 mg/kg/day ABT-263, 16 mg/kg/day AZD8055, combination ABT-263/AZD8055, or no treatment. Chest and upper abdomen were imaged by MRI on the day
before starting treatment and on day 21 of treatment. For each animal, the largest single lung tumor that was histologically confirmed to be a high-grade neu-
roendocrine tumor was measured radiographically, and volume was computed. The percentage of tumor volume change for each animal is plotted as a single circle,
with black bars indicating mean and SEM. Also included for comparison is the percentage of tumor volume change by MRI when equivalent GEMMs were treated
with cisplatin (7 mg/kg IP on days 1 and 8) and etoposide (10 mg/kg on days 2 and 9). Notably, the follow-up imaging time point for the chemotherapy-treated
animals was 28 d. Unpaired two-tailed t tests for statistical significance comparing tumor volume percentage change between pairs of datasets were performed.
Untreated versus ABT-263/AZD8055: P = 0.0222. AZD8055 versus ABT-263/AZD8055: P = 0.00350. ABT-263 versus ABT-263/AZD8055: P = 0.0333. Cisplatin/etoposide
versus ABT-263/AZD8055: 0.1589 (not significant). (C–J) Representative examples of MRI images (with tumors outlined in green) on day 1 and day 21 of a 21-d
treatment period, with the treatment indicated. The asterisk in G and H indicates additional tumor in a separate lobe, which is not included in measurements. (Scale
bar: 5.0 mm.) (K–N) A GEMM SCLC tumor was dissected from the lung and implanted s.c. into a NSG mouse. An established tumor in the NSG mouse was then
divided and s.c. implanted directly into four nu/nu NSGmice. There was no in vitro intermediate. Once tumors were established, nu/nu mice were treated for 3 d
with (K) vehicle for both drugs, (L) AZD8055 (16 mg/kg/qd), (M) ABT-263 (80 mg/kg/qd), (N) ABT-263 (80 mg/kg PO daily), and AZD8055 (16 mg/kg PO daily).
Tumors were collected and fixed 3 h after the final treatment. Sections from tumor were stained to detect CC3, shown as brown stain. (Scale bar: 100 μm.)
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These data indicate substantial activity of this combination in a third
type of SCLC preclinical model and demonstrate that, in a SCLC
PDX model, AZD8055 down-regulates MCL-1 to sensitize SCLC
to ABT-263.
Efficacy of Low-Dose ABT-263 Plus AZD8055 in Vitro and in Vivo.
Therapeutic dosing in humans is sometimes limited by drug tox-
icities that often preclude sufficient target inhibition in patients. The
synergistic effect of the ABT-263/AZD8055 combination promp-
ted us to test whether lower doses of either AZD8055 or ABT-
263 could still efficiently suppress cell viability and demonstrate
in vivo efficacy. In human SCLC cell lines, we found that even
low-nanomolar doses of AZD8055 (5 or 16.66 nM) were suffi-
cient to sensitize SCLCs to ABT-263 (100 nM) (Fig. 6A). This
sensitization to low-dose AZD8055 was also observed in the ex
vivo cell lines derived from SCLC GEMMs (SI Appendix, Fig.
S11B). Similarly, a low dose of ABT-263 (3.3 nM) was sufficient
to strongly suppress cell viability in combination with 50 nM
AZD8055 (SI Appendix, Fig. S13). In the H211 cell line, which is
sensitive to single-agent ABT-263 in vitro and in vivo (19), ad-
dition of AZD8055 further sensitized cells to ABT-263 (Fig. 6A).
Furthermore, in the presence of ABT-263, p4E-BP1 was almost
fully suppressed and MCL-1 was significantly down-regulated
by low-nanomolar doses of AZD8055 (Fig. 6B). In the dose–
response analyses, the amount of apoptosis induced by the combi-
nation was inversely related with the amount of MCL-1 protein
remaining in response to increasing doses of AZD8055 (Fig. 6C).
These in vitro findings prompted us to assess lower doses of
AZD8055 in vivo. Strikingly, a low dose of 2 mg/kg of AZD8055 (Fig.
6D, compared with 16 mg/kg, Fig. 3E) in combination with ABT-263
(80 mg/kg) was sufficient to induce regressions in the H1048 SCLC
xenograft model.
Discussion
Direct targeting of apoptotic regulators has emerged as an effective
therapeutic approach in cancer. One such class of compounds
includes BH3 mimetics, such as ABT-263, which block the binding of
BCL-2 and BCL-XL to BIM and other proapoptotic proteins. In this
study, we examined the efficacy of ABT-263 across a panel of cancer
cell lines and observed that the ratio of BIM to MCL-1 predicted
sensitivity (Fig. 1 and SI Appendix, Fig. S1). These data agree with
a recent report by Roberts et al. showing that a high BIM to MCL-1
ratio indicated a favorable response to ABT-263 in nine patients with
chronic lymphocytic leukemia (11).
There is significant interest in further developing BH3 mimetics to
treat SCLC, and thus we specifically sought to improve the efficacy of
ABT-263 in these cancers. We found that, although levels of BIM
were relatively high in SCLC lines (Fig. 1D), MCL-1 levels were also
relatively high, contributing to ABT-263 resistance (SI Appendix, Fig.
S5E). Thus, high BIM levels may “prime” SCLC for apoptosis and in
this way contribute to the sensitivity of SCLC to ABT-263. However,
the lack of sensitivity of SCLC to ABT-263 in the clinic may be
a result of high MCL-1 levels in these cancers. Therefore, we used
these data as a rationale to develop a novel targeted therapy for
SCLC based on the intrinsic high levels of BIM and the need to
suppress MCL-1 (via TORC inhibition) to sensitize to ABT-263. The
ABT-263/TORC1/2 inhibitor combination strategy was more
effective than either agent alone, not only in increasing the in-
duction of apoptosis, but also in suppressing proliferation. In-
ducing both apoptosis and growth arrest recapitulates the
effects of other successful targeted therapy paradigms (2), in-
cluding EGFR inhibitors for EGFR mutant lung cancers and
ALK inhibitors for ALK-positive lung cancers.
Notably, the enhanced induction of apoptosis and tumor re-
gression by the combination of ABT-263 and AZD8055 was achieved
even with low concentrations of AZD8055 in both cell lines and
mouse xenografts and was directly correlated with the relative re-
duction in MCL-1 protein level (Fig. 6). This suggests that AZD8055
may be effectively combined with ABT-263 even at doses that
would otherwise be subtherapeutic as a single agent, widening
the potential therapeutic window of this combination. As other
BH3 mimetics are being currently developed in the clinic, it will
be interesting to determine the differential activity of each to
build on the promising concept of combining TORC inhibitors
with BH3 mimetics.
A recent report by Gardner et al. demonstrated that rapamycin
sensitized several SCLC human cell lines and PDXs to the struc-
turally related BH3-mimetic ABT-737 (35). However, our study
reveals significant differences between the two approaches. Unlike
the TORC catalytic site inhibitor, rapamycin fails to significantly
down-regulate MCL-1 (SI Appendix, Fig. S8A). This finding is con-
sistent with results demonstrating that TORC1/2 catalytic inhibitors
more effectively suppress 4E-BP1 phosphorylation and cap-depen-
dent translation than rapamycin or rapalogs (31, 33). Thus, the
TORC catalytic inhibitor is uniquely capable of down-regulating
MCL-1 protein expression, which is key for the combination to in-
duce apoptosis. Indeed, we found that addition of rapamycin did not
consistently increase the amount of apoptosis induced by ABT-263
(SI Appendix, Fig. S8B). Another major difference between these
therapeutic approaches is that the AZD8055/ABT-263 combination
appears effective in low-BCL-2–expressing SCLCs (NCI-H82 and
NCI-H446, Figs. 3 B and E and 6A), which Gardner et al. (35) found
were resistant to the combination of rapamycin with ABT-737.
In contrast to the findings reported by Gardner et al. (35), we did
not observe that ABT-263, rapamycin, or AZD8055 consistently af-
fected BAX levels (Figs. 3F and 5B and SI Appendix, Fig. S8C). One
Fig. 5. Addition of AZD8055 to ABT-263 sensitizes a PDX model of SCLC.
(A) Pieces of a patient-derived SCLC tumor were implanted into NSG mice
and monitored for subsequent growth. Upon growing to ∼150–300 mm3,
tumors were treated with ABT-263 (80 mg/kg/qd) or ABT-263 (80 mg/kg/qd)
plus AZD8055 (16 mg/kg/qd). AZD8055 was given ∼1.5 h before ABT-263 for
combination treatments. Tumor measurements were performed approxi-
mately three times per week by calipers, and the average tumor volume + SEM
for each cohort is displayed. Treatment start is indicated by an arrow.
(B) Approximately 3 h after final drug administration, tumors were surgically
excised and tumor lysates were prepared and subjected toWestern blot analyses
and probed with the indicated antibodies. ABT-263–treated and ABT-263 and
AZD8055 combination–treated (ABT+AZD) tumors were compared to two un-
treated tumors (No Rx). Each number represents a tumor from a unique mouse.
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possibility for this difference is that Gardner et al. (35) assessed for
changes in BAX expression after more prolonged treatment (1 d
to 1 w). Although we did not detect BAX changes after >14 d of
treatments in the H1048 xenograft model (Fig. 3F) or in the PDX
model of SCLC (∼50 d of treatment), we assayed for BAX expres-
sion only at shorter time points in vitro (16 h). Thus, BAX regulation
through TORC1 inhibition may be a later event in some models of
SCLC. Importantly, Gardner et al. (35) observed that the mTOR
pathway was active in all of the PDX models that they studied, fur-
ther supporting the concept that combining mTORC catalytic
site inhibitors with BH3 mimetics in SCLC could be beneficial.
Interestingly, we observed that the BIM to MCL-1 ratio predicted
sensitivity to ABT-263 not only in SCLC, but also across a large panel
of cancer cells encompassing a wide range of malignancies (Fig. 1B
and SI Appendix, Fig. S1D). We indeed recently reported that com-
bination ABT-263 and AZD8055 also showed efficacy in KRAS and
BRAF mutant colorectal cancers (7). In that study, we demonstrated
that AZD8055 led to loss of MCL-1 in those cancers, thereby sen-
sitizing to ABT-263. However, this combination therapy was not
effective in KRAS and BRAF wild-type colorectal cancers, where
TORC1/2 inhibition failed to suppress MCL-1. Thus, it is likely that
this combination therapy may specifically be effective for cancers in
which TORC1/2 inhibition suppresses MCL-1 expression.
We extended our study beyond the more traditional preclinical
strategies by using both a SCLC GEMM model and a PDX from
a patient with SCLC. Importantly, each autochthonous tumor in the
SCLC GEMM model, although initiated by inactivation of Tp53
and Rb1, develops a unique set of additional genetic alterations (39).
Furthermore, tumors themselves are heterogeneous, harboring mul-
tiple distinct subclones (39). Autochthonous GEMM tumors may
therefore more closely recapitulate the genetic heterogeneity found
in human SCLC tumors (24, 40, 41) and may be a more rigorous
assay for therapeutic efficacy than in vitro studies or mouse xenograft
models. They also model the tumor microenvironmental features and
immune interactions of human disease more fully than s.c. xenografts
in immune-compromised hosts. The fact that we consistently ob-
served stabilization or regression of tumors in response to combina-
tion of ABT-263 and AZD8055 in the GEMM, compared with either
drug alone, further supports the notion that this combination may be
more broadly active in patients than ABT-263 monotherapy. Notably,
of six autochthonous tumors treated with ABT-263 alone, one
showed significant regression whereas the other five significantly
progressed. This range of sensitivities also mirrors the range of sen-
sitivities to ABT-263 in human cell lines and in patients (19, 24).
There was a trend toward GEMM tumors responding more to
ABT-263 and AZD8055 than to the standard of care chemotherapies
used in patients, cisplatin and etoposide. The relative lack of response
of the GEMM tumors to cisplatin and etoposide is interesting be-
cause, by contrast, human SCLC tumors have a response rate of
∼50% to combination platinum and etoposide (42). Consistent
with our findings, Singh and colleagues (43) showed that Tp53/
Rb1-deleted SCLC GEMMs were only modestly sensitive to
combination carboplatin and irinotecan, which have similar clini-
cal efficacy as cisplatin and etoposide in patients (42, 44). The
SCLC GEMM may therefore more closely resemble a chemo-
therapy-resistant subset of human SCLC. If this is true, then our
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Fig. 6. Low doses of AZD8055 sensitize SCLC to ABT-263. (A) SCLC cell lines were treatedwith no drug (Media), 100 nMABT-263 (ABT-263 only), or 100 nMABT-263 in
combinationwith the indicateddoseofAZD8055 (ranging from5to5,000nMAZD8055) for 7d. Thenumberofviable cellswasdeterminedbyCellTiter-Gloandpresented
as fold-changeof cells comparedwithday0 (i.e., negativevalues represent lossof cells fromday0). ErrorbarsareSDofcells treated in triplicate. (B)H1048cellswere treated
with the indicated dose of AZD8055 with 100 nMABT-263 or 100 nMABT-263 alone (–) for 16 h, and equal amounts of lysates were subjected toWestern blot analyses
and probedwith the indicated antibodies. (C) The amount ofMCL-1 protein relative to GAPDH as determined by quantification on a SynGene GBoxwas plotted against
the amount of apoptosis induced by the corresponding 72 h drug treatments (as determined by FACS analysis of the percentage of Annexin-V–positive cells, treatment
minusno-treatmentcontrol).Note:AZD8055treatmentswere in thepresenceof100nMABT-263,as in (B). For the linear regressionanalysis, theR2valuewas0.939andthe
P valuewas 0.007. (D) H1048 cells were grown as xenograft tumors in Nu/Numice.When tumors reached∼100–200mm3,micewere randomized into treatment cohorts:
control (no drug), 2 mg/kg AZD8055, or the combination of AZD8055 (2 mg/kg) and ABT-263 (80 mg/kg). AZD8055 was given ∼1.5 h before ABT-263 for combination
treatments. Tumor measurements were performed approximately three times per week by calipers, and the average tumor volume± SEM for each cohort is displayed.
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study supports the use of the combination of ABT-263 and
TORC1/2 inhibition even in second line setting in patients. Al-
ternatively, it is possible that we did not achieve sufficient levels of
cisplatin and etoposide in the mice to induce the extent of tumor
regression often seen in patients.
Our PDX study demonstrated lack of efficacy of single-agent
ABT-263, consistent with the lack of efficacy observed with
single-agent ABT-737 by Gardner et al. (35). The combination,
however, induced regressions of all of the combination-treated
tumors (Fig. 5A). Taken together with the potent efficacy dem-
onstrated in the human xenograft mouse models of SCLC
(Fig. 3) and the GEMM model (Fig. 4), the effect of the com-
bination of AZD8055 and ABT-263 was consistent and pro-
found across several mouse models, even at low concentrations
of AZD8055 (Fig. 6D).
Overall, we found that high BIM levels helped promote sensi-
tivity to BCL-2/BCL-XL inhibitors in SCLC, but efficacy was miti-
gated by MCL-1. The addition of TORC1/2 inhibitors to BCL-2/
BCL-XL inhibitors in SCLCs can lead to marked tumor responses
in an array of complementary mouse models and therefore may
improve the efficacy of BH3 mimetics for the treatment of SCLC.
Materials and Methods
All materials and methods are described in SI Appendix. These include information
on cell lines, Western blotting, immunoprecipitation, plasmid preparation, siRNA
transfections and shRNA transductions, viability assays, FACS death and cell cycle
assays, mouse experiments, and statistical methods.
All studies inGEMMandallograftmodelswereperformedunder an Institutional
Animal Care and Use Committee- and Massachusetts Institute of Technology
Committee on Animal Care-approved animal protocol.
The mouse xenografts and patient-derived xenografts were performed in ac-
cordance with the Massachusetts General Hospital Subcommittee on Research
Animal Care.
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